BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Deals

  Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M

  The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.

  November 29, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  2-Year Old Codiak Lands Another $76.5M, Bringing Its Total Raise to $168.5M

  The company indicates it plans to use the proceeds from the latest financing to move its lead product candidates into clinical trials and to continue developing its exosome therapeutic platform.

  November 29, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  BioForest

  Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now

  Omeros is getting a lot of love from investors and analysts these days.

  November 29, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Biocartis Scores 80M Euros to Fund Expansion of Its Idylla Test Menu

  The firm said it sold the shares at an issue price of €12.50 each, and that the total 6.4 million shares represent approximately 14.3 percent of its outstanding shares.

  November 29, 2017

   · 

  1 min read
• 

  Business

  Troubled Otonomy Cuts Jobs, Ceases Programs Related to Otiprio

  Otonomy said dropping the program and terminating the employees will provide a cash savings of more than $20M in 2018.

  November 29, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Job Trends

  bluebird to Hire at New In-House Manufacturing Facility in North Carolina

  The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.

  November 29, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Meet the Scientist Who Admits His MS Therapy is ‘Largely Ineffective.’

  What many hope will be the final chapter in an unfortunate saga in multiple sclerosis research appears to have been written by the scientist who started the affair in the first place.

  November 29, 2017

   · 

  1 min read
• 

  Drug Development

  Mind-Blowing: Amgen’s Aimovig Halves Length of Migraine Attacks in Phase III Study

  Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half.

  November 29, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Alkermes Allegedly Fired 3 Female Employees Who Raised Concerns of Bias

  After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported.

  November 29, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Why This Small SoCal Biotech’s Pipeline Makes it Flushed for Growth

  Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone’s interested in fast-growing stocks.

  November 29, 2017

   · 

  3 min read

   · 

  Mark Terry